Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Nature Genetics

Volumn 45, Issue 12, 2013, Pages 1446-1451

  Robinson, Dan R ^a   Wu, Yi Mi ^a   Vats, Pankaj ^a   Su, Fengyun ^a   Lonigro, Robert J ^a   Cao, Xuhong ^a   Kalyana Sundaram, Shanker ^a   Wang, Rui ^a   Ning, Yu ^a   Hodges, Lynda ^a   Gursky, Amy ^a   Siddiqui, Javed ^a   Tomlins, Scott A ^a   Roychowdhury, Sameek ^b   Pienta, Kenneth J ^c   Kim, Scott Y ^d   Roberts, J Scott ^d   Rae, James M ^a   Van Poznak, Catherine H ^a   Hayes, Daniel F ^a   Chugh, Rashmi ^a   Kunju, Lakshmi P ^a   Talpaz, Moshe ^a   Schott, Anne F ^a   Chinnaiyan, Arul M ^a,d   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; BRCA1 PROTEIN; ENDOXIFEN; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FULVESTRANT; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2;

ADULT; AGED; ARTICLE; BREAST METASTASIS; DNA SEQUENCE; ENDOMETRIUM CANCER; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENE FUSION; GENE MUTATION; HUMAN; IN VITRO STUDY; LIGAND BINDING; MISMATCH REPAIR; PRIORITY JOURNAL; RNA SEQUENCE; SITE DIRECTED MUTAGENESIS; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84888381937     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2823     Document Type: Article

References (40)

1. Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17, 297-303 (2011).
2. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
3. Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
4. Welch, J. S. et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. J. Am. Med. Assoc. 305, 1577-1584 (2011).
5. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001). (Pubitemid 32743979)
6. Korpal, M. et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3, 1030-1043 (2013).
7. Joseph, J. D. et al. A clinically relevant androgen receptor mutation confers resistance to 2nd generation anti-androgens enzalutamide and ARN-509. Cancer Discov. 3, 1020-1029 (2013).
8. Ariazi, E. A., Ariazi, J. L., Cordera, F. & Jordan, V. C. Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 6, 181-202 (2006).
9. Riggins, R. B., Schrecengost, R. S., Guerrero, M. S. & Bouton, A. H. Pathways to tamoxifen resistance. Cancer Lett. 256, 1-24 (2007). (Pubitemid 47333324)
10. Lønning, P. E. & Eikesdal, H. P. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr. Relat. Cancer 20, R183-R201 (2013).
11. Ingle, J. N. et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. 24, 1052-1056 (2006). (Pubitemid 46638801)
12. Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
13. Wu, Y. M. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647 (2013).
14. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
15. Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem. Biophys. Res. Commun. 237, 752-757 (1997). (Pubitemid 27434760)
16. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
17. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
18. Huang, H. J., Norris, J. D. & McDonnell, D. P. Identification of a negative regulatory surface within estrogen receptor provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol. Endocrinol. 16, 1778-1792 (2002). (Pubitemid 34828088)
19. Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998). (Pubitemid 29019045)
20. Skafar, D. F. Formation of a powerful capping motif corresponding to start of "helix 12" in agonist-bound estrogen receptor-contributes to increased constitutive activity of the protein. Cell Biochem. Biophys. 33, 53-62 (2000).
21. Carlson, K. E., Choi, I., Gee, A., Katzenellenbogen, B. S. & Katzenellenbogen, J. A. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36, 14897-14905 (1997). (Pubitemid 27524414)
22. Weis, K. E., Ekena, K., Thomas, J. A., Lazennec, G. & Katzenellenbogen, B. S. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 10, 1388-1398 (1996). (Pubitemid 26423229)
23. Pearce, S. T., Liu, H. & Jordan, V. C. Modulation of estrogen receptor function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J. Biol. Chem. 278, 7630-7638 (2003). (Pubitemid 36800772)
24. Zhao, C. et al. Mutation of Leu-536 in human estrogen receptor-alters the coupling between ligand binding, transcription activation, and receptor conformation. J. Biol. Chem. 278, 27278-27286 (2003). (Pubitemid 36876885)
25. Ellis, M. J. et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. J. Am. Med. Assoc. 302, 774-780 (2009).
26. Swaby, R. F. & Jordan, V. C. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin. Breast Cancer 8, 124-133 (2008). (Pubitemid 351655926)
27. Sokolosky, M. L. et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2, 538-550 (2011).
28. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
29. Shrestha, Y. et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 31, 3397-3408 (2012).
30. Barone, I., Brusco, L. & Fuqua, S. A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin. Cancer Res. 16, 2702-2708 (2010).
31. Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
32. Fisher, B. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86, 527-537 (1994). (Pubitemid 24111008)
33. Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
34. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
35. Kim, D. & Salzberg, S. L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 12, R72 (2011).
36. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
37. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
38. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
39. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
40. Lonigro, R. J. et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 13, 1019-1025 (2011).